# A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

> **NCT07492680** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 260 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** BMS-986504
- **DRUG:** Daraxonrasib
- **DRUG:** Nivolumab + Relatlimab FDC
- **DRUG:** Temozolomide
- **DRUG:** Pumitamig
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT07492680
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-17
- **Primary completion:** 2032-05-20
- **Final completion:** 2032-05-20
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07492680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07492680, "A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07492680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*